AI Magazine

Business Chief

Business Chief Asia

Business Chief Middle East

Business Chief UK & Europe

ClimateTech Digital

Construction Digital

Cyber Magazine

Data Centre Magazine

EV Magazine

Energy Digital

FinTech Magazine

Finance Chief

Food and Drink Digital

HR Chief

Healthcare Digital

InsurTech Digital

Manufacturing Digital

March8

Marketing Chief

Mining Digital

Procurement Magazine

Scope 3 Magazine

Supply Chain Digital

Sustainability Magazine

Technology Magazine

Telco Magazine

Magazine

Companies

Interviews

Videos

Events

Lists

Content

About

Editorial

Advertise

Press Releases

PR Newswire

GlobeNewswire

More

Articles

Top 10

News & Articles

Magazines

Company Reports

Reports & Whitepapers

Leadership

Finance

Tech & AI

Digital Strategy

People & Planet

Topics

Asia & ANZ

Middle East & Africa

US & Canada

Region

The CXO Summit

Deloitte: Why AI Investment Will Boost Business Productivity

How is Sustainability Reshaping Business Value?

Is Chief Sustainability Officer Women's Route to C-Suite?

How Flyfish Aims to Solve Business Banking Fragmentation

Michael Zetser

How Flyfish Aims to Address Financial Fragmentation for SMEs

Digitalisation Creates a Competitive Edge in Real Estate

Banco Comercial Português, S.A. informs about Interim report on the transactions conducted under the Share Buy-Back Programme 
 Attachment

<ul id="gnw_attachments_section-items">
 <li>
 <a target="_blank" href="https://www.globenewswire.com/Tracker?data=yArLT8LOpCZ3Q7KAxZG4z4HwZr16qkjBXLIshcuUVmB6IE1Vat05xuzrOVWS4CSML6TOzD7HYMvDSWFgrWcHJVWxznhIAzCvzBOgaumDGTneWezRze79qJnPZyiKE0Pk1xyzewCN5UWyuLoZBh7bN6mF5UenpGg_DTUrrk2UfoA=" title="20260821 SBB EN" rel="nofollow">20260821 SBB EN</a>
 </li>
 </ul>
 <img alt="" src='https://ml-eu.globenewswire.com/media/MDY1ZDZjNjktOGFjYi00NDQ2LTkzN2UtZTRiZDk1ZDRlOTBmLTEwMTQyMTYtMjAyNi0wOC0yMS1lbg==/tiny/Banco-Comercial-Portugues-S-A-.png' referrerpolicy='no-referrer-when-downgrade' />

Banco Comercial Português, S.A. informs about Interim report on the transactions conducted under the Share Buy-Back Programme

Dubai, UAE, Aug. 21, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- <img height="390" name="GNW_RichHtml_IMG" src="https://ml.globenewswire.com/Resource/Download/0829bd94-d25a-4f29-b9cd-f01e1d44d81d/image1.jpeg" width="695" data-dpi="220" data-filename="image1.jpeg" /> The free online tool helps UAE businesses estimate their ICV score, identify improvement areas and prepare for formal certification <a href="https://taxadepts.com/" rel="nofollow" target="_blank" title="">ADEPTS</a> Chartered Accountants, a UAE-based professional services firm, has launched the country’s first online ICV Score Calculator. The free tool enables businesses to obtain a preliminary estimate of their In-Country Value score within minutes. Developed in line with the Ministry of Industry and Advanced Technology’s National ICV framework, the calculator applies the core methodology, formulas, and scoring principles used in the official assessment process. “Businesses have traditionally treated ICV as a certificate obtained once a year, rather than a commercial score that should be monitored and managed continuously,” said <a href="https://www.linkedin.com/in/muhammad-aaliyan-ibrahim-2418b19b/" rel="nofollow" target="_blank" title="">Aaliyan Ibrahim, founder and managing partner of ADEPTS</a>. “This tool allows leadership teams to understand their position early, identify opportunities for improvement, and make more informed decisions before beginning the formal certification process.” The calculator evaluates key ICV components, including third-party expenditure, investment in the UAE, Emiratisation, expatriate manpower costs, export revenue, and the Advanced Technology and Sustainability bonus. It automatically adjusts the calculation depending on whether the business is a Goods Manufacturer or Service Provider. After entering their financial and operational data and verifying their email address, users receive an itemised breakdown of their estimated ICV score. ADEPTS emphasised that the calculator is intended for preliminary assessment, benchmarking, and internal planning. It does not replace an official ICV certificate, which must be reviewed and issued by an authorised certifying body based on verified financial information and supporting documentation. “ICV performance is shaped by procurement, investment, workforce, and operational decisions made throughout the year,” Ibrahim added. “Understanding the impact of those decisions early can help businesses strengthen their ICV position and compete more effectively.” The launch reinforces ADEPTS’ growing position in the UAE’s professional services market. It also reflects the firm’s continued investment in practical digital solutions that make complex regulatory requirements easier for businesses to understand and manage. The ADEPTS ICV Score Calculator is now available at <a href="https://taxadepts.com/icv-score-calculator" rel="nofollow" target="_blank" title="">taxadepts.com/icv-score-calculator</a> . Media Info Website :  <a href="https://taxadepts.com/" rel="nofollow" target="_blank" title="">https://taxadepts.com/</a> Email     :  info@taxadepts.com Information contained on this page is published by <a href="https://sptechsol.com/" rel="nofollow" target="_blank" title="">SP Tech Solutions</a> and content provided by authorized third party content provider.  SP Tech Solutions and this Site make no warranties or representations in connection therewith. <img alt="" src='https://ml.globenewswire.com/media/ZDdjNDAxNjQtZjliYy00ZWI4LWI1YzUtNjI4NjdjMjU5OTg0LTUwMDE2Njg3Mi0yMDI2LTA4LTIxLWVu/tiny/ADEPTS.png' referrerpolicy='no-referrer-when-downgrade' />

ADEPTS launches UAE’s first online ICV score calculator

<div style="float:right;padding:0 0 15px 20px;margin:15px 0 20px 20px;width:300px">
 DeHealth
 <figure>
 <img src="https://ml.globenewswire.com/Resource/Download/8569eeaa-415b-4223-8f14-dce4b55e0ce9" title="DeHealth" alt="DeHealth" />
 <figcaption>DeHealth</figcaption>
 </figure>
</div>Kyiv, Ukraine, Aug. 21, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- Co-founders of the <a href="https://dehealth.ua/en" rel="nofollow" target="_blank" title="DeHealth Charitable Foundation">DeHealth Charitable Foundation</a>, Anna Bondarenko and Denys Tsvaig, continue to support Ukraine through the Foundation's humanitarian and medical mission, which has now surpassed USD 3.2 million in documented assistance. Alongside the Foundation's activities, Bondarenko is developing her own public economic agenda focused on Ukraine's long-term economic development and independence. Since the beginning of Russia's full-scale invasion of Ukraine, the DeHealth Charitable Foundation has organized more than 200 targeted deliveries of medical and humanitarian aid, with a total documented value exceeding USD 3.2 million. More than 50 military units and other recipients across Ukraine have received support through the Foundation. The assistance has been secured through an international network rather than through monetary fundraising among Ukrainian citizens. For Bondarenko, humanitarian assistance addresses only one part of a much larger challenge. The key question now, in her view, is what economic model can make Ukraine stronger and more resilient for decades to come. Anna Bondarenko's Economic Agenda Alongside her work with the Foundation, Anna Bondarenko is developing her own public economic agenda dedicated to Ukraine's long-term economic future. Her recent public materials examine Ukraine's post-war economy, energy capacity, technological infrastructure, and potential models for strengthening the country's economic independence. Her publications and public appearances have gained wide exposure in Ukraine, as well as among audiences in the United States, Canada, and European Union countries. One of the central themes of Bondarenko's personal agenda is the need for Ukraine to move beyond long-term dependence on external assistance by developing its own assets, infrastructure, and sustainable sources of economic growth. Her vision also involves creating broader opportunities for citizens through the development of energy infrastructure and technology, the attraction of international capital, and the use of domestic economic resources. This agenda is Bondarenko's own independent public initiative and is not part of the DeHealth Charitable Foundation's programs or activities. Context of the Current Information Environment As Bondarenko's public profile has grown and her personal economic agenda has expanded, Anna Bondarenko, Denys Tsvaig, and DeHealth have become the subjects of online publications containing claims they characterize as false and defamatory. According to the Foundation, virtually identical materials have appeared across numerous websites, mirror domains, and recently created online resources, resulting in multiple copies of the same allegations being distributed across the internet. The origins of some of the resources involved in this distribution have raised concerns. Certain websites within this ecosystem have previously been subject to sanctions, blocking, or other official restrictions, while some resources have been associated with the pro-Russian information environment. DeHealth and its founders emphasize that the ownership, affiliations, and sanctions status of each individual website should be assessed separately and established on the basis of official information. The latest wave of publications emerged after a number of previously published URLs were de-indexed from or restricted in certain Google search results following requests submitted under mechanisms provided by European data protection law, including the General Data Protection Regulation (GDPR). <blockquote> "Repeating a claim does not turn it into a fact. When virtually identical allegations appear across numerous mirror websites, it is important to establish where they originated, what evidence supports them, and how they are being distributed," stated Denys Tsvaig, co-founder of Dehealth. </blockquote> DeHealth and its founders emphasize that removing a page from search results does not mean deleting the article from the website on which it was originally published. The original material may remain accessible online even if a particular URL no longer appears in certain search results. What Comes Next For DeHealth and its founders, the humanitarian mission continues to be measured by concrete results: more than 200 targeted deliveries and over USD 3.2 million in documented assistance since the beginning of the full-scale invasion. For Bondarenko personally, however, the next stage of her own work is broader in scope. Her attention is increasingly focused on the economic architecture Ukraine will need in the future: energy and technological infrastructure, international capital, domestic economic assets, and mechanisms capable of creating long-term opportunities within the country. Online attacks do not change that direction. For Anna Bondarenko, the central question is not what is being written today, but what Ukraine will be able to build next. About Anna Bondarenko and Denys Tsvaig Anna Bondarenko and Denys Tsvaig are co-founders of the DeHealth Charitable Foundation and the international DeHealth group of companies, which has developed technologies for preventive health. Since the beginning of Russia's full-scale invasion of Ukraine, the Foundation has organized more than 200 targeted deliveries of medical and humanitarian assistance, with a total documented value exceeding USD 3.2 million. Alongside the Foundation's activities, Bondarenko has developed her own public agenda focused on Ukraine's long-term economic resilience, the development of energy and technological infrastructure, and international investment partnerships. About the DeHealth Charitable Foundation The <a href="https://dehealth.ua/en" rel="nofollow" target="_blank" title="DeHealth Charitable Foundation">DeHealth Charitable Foundation</a> coordinates humanitarian and medical assistance for Ukraine. The Foundation has organized more than 200 targeted deliveries for over 50 military units and other recipients across the country. The Foundation operates without conducting monetary fundraising among Ukrainian citizens, securing medicines, medical equipment, and essential supplies through its international network. 
 Attachment

<ul id="gnw_attachments_section-items">
 <li>
 <a target="_blank" href="https://ml.globenewswire.com/Resource/Download/8569eeaa-415b-4223-8f14-dce4b55e0ce9" title="DeHealth" rel="nofollow">DeHealth</a>
 </li>
 </ul>
<pre>Contact
DeHealth
office@dehealth.world
</pre> <img alt="" src='https://ml.globenewswire.com/media/OWI3MWJmZmItODNhNy00MTc4LThjZmQtNTY3YWRhMGJiNGMxLTUwMDE2Njg2Ni0yMDI2LTA4LTIxLWVu/tiny/DeHealth.png' referrerpolicy='no-referrer-when-downgrade' />

DeHealth Foundation by Anna Bondarenko and Denys Tsvaig Surpasses $3.2 Million in Medical Aid to Ukraine

A Milestone in Customer Satisfaction and Global Reach for Ecuadorian ExcellenceQuito, Ecuador, Aug. 21, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- Ecualama, a leader in the production and export of high-quality Ecuadorian products, proudly announces a significant milestone: receiving 2,800 customer reviews from buyers around the globe. This achievement underscores the company's commitment to delivering exceptional organic and sustainable agricultural goods. Founded with a vision to bring the best of Ecuadorian produce to the world, Ecualama has consistently prioritized quality and sustainability. The company’s diverse range of products has not only captured the hearts of local consumers but has also made a substantial impact on international markets. The 2,800 reviews reflect the trust and satisfaction of customers who have experienced the superior quality of Ecualama's offerings. These reviews, collected from various platforms, highlight the company's dedication to excellence and its ability to meet the diverse needs of its clientele. "Reaching this milestone is a testament to our unwavering commitment to quality and customer satisfaction," said Nataliya Zhestkova, CEO of Ecualama. "We are grateful to our customers for their trust and support, which inspires us to continue delivering the finest Ecuadorian products worldwide." Ecualama's success is rooted in its sustainable practices and its focus on organic agriculture. By prioritizing environmentally friendly methods, the company not only contributes to the health of the planet but also ensures that its products are of the highest quality. As Ecualama continues to grow, it remains dedicated to expanding its reach and enhancing its product offerings. The company is poised to further its impact on the global stage, bringing the rich flavors and natural goodness of Ecuador to more consumers worldwide. For more information about Ecualama and its products, visit their website at <a href="https://ecualama.com/" rel="nofollow" target="_blank" title="ecualama.com">ecualama.com</a> Press Inquiries Nataliya Zhestkova info [at] ecualama.com +442036951183 <a href="https://ecualama.com/" rel="nofollow" target="_blank" title="">https://ecualama.com/</a> Quito Ecuador <img alt="" src='https://ml.globenewswire.com/media/ODMwN2JiZDUtY2M1OC00MjBlLTgwNTUtOGM4NmFjZGM1M2IyLTUwMDE2Njg2My0yMDI2LTA4LTIxLWVu/tiny/Ecualama.png' referrerpolicy='no-referrer-when-downgrade' />

A Milestone in Customer Satisfaction and Global Reach for Ecuadorian Excellence

Ecualama Celebrates 2,800 Customer Reviews From Buyers Worldwide

Transparency notification by BNP Paribas Asset Management Holding and BNP Paribas Cardif In accordance with article 14, § 1 of the law of 2 May 2007 on the disclosure of major holdings, Umicore was recently notified by BNP Paribas Asset Management Holding and BNP Paribas Cardif that they had crossed below the legal threshold of 3% of direct voting rights on 18 August. Summary of the move: <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; margin-left:0; width:497.85pt; border-collapse:collapse ;"><tr><td style="width:170.14px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">Date on which the threshold was crossed</td><td style="width:115.4px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">Date of notification</td><td style="width:132.94px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">Direct voting rights after the transaction</td><td style="width:148.6px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">Equivalent financial instruments after the transaction</td><td style="width:96.74px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">Total</td></tr><tr><td style="width:170.14px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">18 August 2026</td><td style="width:115.4px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">18 August 2026</td><td style="width:132.94px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">-</td><td style="width:148.6px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">-</td><td style="width:96.74px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">-</td></tr></table> Notification from BNP Paribas Asset Management Holding and BNP Paribas Cardif: The most recent notification contains the following information: <ul type="disc"><li style="margin-bottom:12pt; text-align:justify;">Date of notification: 18 August 2026</li><li style="margin-bottom:12pt; text-align:justify;">Date on which the threshold was crossed: 18 August 2026</li><li style="margin-bottom:12pt; text-align:justify;">Threshold of direct voting rights crossed downwards: 3%</li><li style="margin-bottom:12pt; text-align:justify;">Notification by: BNP Paribas Asset Management Holding and BNP Paribas Cardif</li><li style="margin-bottom:12pt; text-align:left;">Denominator: 246,400,000</li><li style="margin-bottom:12pt; text-align:left;">Reason for notification: Acquisition or disposal of voting securities or voting rights, downwards crossing of the lowest threshold</li></ul> Transparency notifications and the full chain of controlled undertakings through which the holding is effectively held are available on the <a href="https://www.globenewswire.com/Tracker?data=cZYqlM2WzOiyzZLUfp2dQEqttP7yuQv1ZT6d4G_tuHL5zFTlW6p-6Z_QHrkWbA20qdFgOeQLYuyog4kypjjn02QB98vgQT2Gz0avnJ3mJ6rFJnbdYiMZZMe7h9S8TiBktZP0bAUM1vOjUZjMS-pWjOPTxu7e7cKa4F3NFFiBIpCtFtoYjSTs4IdFZqvmD6HL" rel="nofollow" target="_blank" title="Transparency Declaration section">Transparency Declaration section</a> of Umicore's website. About Umicore Umicore is a global advanced materials and recycling Group. Leveraging decades of expertise in materials science, metallurgy, chemistry, and metals management, Umicore transforms precious and critical metals into functional technologies that enable everyday applications. Its unique circular business model ensures that these critical elements are continuously refined and recycled, to be reintegrated in new applications. Umicore’s four Business Groups – Catalysis, Recycling, Specialty Materials and Battery Materials Solutions – offer materials and solutions addressing resource scarcity and the growing need for functional materials for clean technologies, clean mobility and a connected world. Through tailored and cutting-edge products and processes they drive innovation and sustainability. Umicore generates the majority of its revenues from, and focuses most of its R&amp;D efforts on, clean mobility and recycling. Its overriding goal of sustainable value creation is rooted in developing, producing and recycling materials for a better life. Umicore’s industrial, commercial and R&amp;D activities, with more than 11,000 employees, are located across the world to best serve its global customer base. Group revenues (excluding metal) reached € 1.9 billion (turnover of € 13.9 billion) in the first half of 2026. For more information <table style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:446.55pt; border-collapse:collapse ;"><tr><td style="width:170.14px;;border-right: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Caroline Kerremans </td><td style="width:160.67px;;border-right: solid black 1pt ; border-left: solid black 1pt ; text-align: right ; vertical-align: middle; vertical-align: top ; ">+32 2 227 72 21 </td><td style="width:264.6px;;border-left: solid black 1pt ; text-align: right ; vertical-align: middle; vertical-align: top ; "><a href="mailto:caroline.kerremans@umicore.com" rel="nofollow" target="_blank" title="">caroline.kerremans@umicore.com</a></td></tr><tr><td style="width:170.14px;;border-right: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Bart Heylen</td><td style="width:160.67px;;border-right: solid black 1pt ; border-left: solid black 1pt ; text-align: right ; vertical-align: middle; vertical-align: top ; ">+32 2 227 73 09 </td><td style="width:264.6px;;border-left: solid black 1pt ; text-align: right ; vertical-align: middle; vertical-align: top ; "><a href="mailto:bart.heylen@eu.umicore.com" rel="nofollow" target="_blank" title="bart.heylen@umicore.com">bart.heylen@umicore.com</a></td></tr></table> <img alt="" src='https://ml-eu.globenewswire.com/media/NjY3NWFjOTUtNDEyZC00NTFiLWE1ZGYtZGMwMjkyYTc5YzZhLTEwMTE4ODYtMjAyNi0wOC0yMS1lbg==/tiny/Umicore.png' referrerpolicy='no-referrer-when-downgrade' />

Umicore - Transparency notification by BNP Paribas Asset Management Holding and BNP Paribas Cardif

<img alt="New Crypto Presale Moonberg Taps $300,000 As XRP Price Prediction Targets $10" height="338" src="https://ml.globenewswire.com/Resource/Download/8b365483-3104-49cf-bee9-0379e49ec89b/new-crypto-presale-moonberg-taps-300-000-as-xrp-price-prediction-targets-10.jpg" width="600" data-dpi="150" data-caption="Crypto News: New Crypto Presale Moonberg Taps $300,000 As XRP Price Prediction Targets $10" data-filename="New Crypto Presale Moonberg Taps $300,000 As XRP Price Prediction Targets $10.jpg" /> ZUG, Switzerland, Aug. 21, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- Moonberg's new crypto presale has now surpassed the $300,000 mark, adding fresh impetus to the project's push toward its next stage as interest builds around its $MBX token and AI-native trading platform. The milestone comes as crypto news increasingly turns toward the next major market opportunities, with the XRP price prediction sharply coming back into focus amid a renewed debate over whether the cryptocurrency could eventually reach $10. For Moonberg, the timing creates an interesting contrast. XRP is an established large-cap asset that has already experienced multiple major market cycles, while Moonberg remains at an earlier point in its development prior to price discovery. As its presale progresses, the project is attempting to woo traders with its agentic suite of tools, with the market seemingly responding positively to tech clearly evident to holders before a dollar was even raised. New Crypto Presale Moonberg Reaches $300,000 Moonberg has now passed $300,000 in its $MBX <a href="https://www.globenewswire.com/Tracker?data=9zFTqQnS60HTLg9PPhmqCRx4cveLcAiI6Krnf-D-PX9LXUQ42Dru22oLgJPCwPa3u2sctUvPnpiKhpu0DJLPlrTc0zeF0iyLjaPt2-ceFy8TdSaYczKzHL8mNVp3W6CJ" rel="nofollow" target="_blank" title="">crypto presale</a>, marking another milestone as the token sale progresses through its early allocations. The staged structure means that available supply and pricing change as the presale advances, giving early participants an opportunity to enter before later stages at a significantly more advantageous entry. With $300,000 now raised, it’s becoming increasingly clear that smart money is positioning itself early, just like XRP holders in 2017. The project is also differentiating itself from many speculative presales through its underlying product. Moonberg's AI-native trading terminal brings together market intelligence, on-chain analysis, wallet data and trading functionality, while its AI agents are designed to help users develop automated trading strategies. That gives the $MBX story an element beyond the presale itself: participants are entering an ecosystem built around a growing AI-trading narrative rather than simply waiting for a product to be developed. For traders who believe AI will play a larger role in crypto markets, the $300,000 milestone could therefore be an important early marker in what could be a generational play. XRP Price Prediction Targets $10 The XRP price prediction has taken on a more ambitious tone in recent months, with several analysts and market publications examining whether the token could eventually reach double digits. <a href="https://www.globenewswire.com/Tracker?data=HRK2Dgf8hZkZhSag0KT3wA2jAT5zGNbrMEd83DaT-LipVbfO_g3rW5MEWsWv6YdCe9Mzg6dsfSWGUL5H73AOADNojJUZ70lHzh_PZgg_m1-XxFBLr5kkGoP00QXuLjL4" rel="nofollow" target="_blank" title="">CoinGabbar</a> recently outlined a technical scenario in which XRP could first target around $3.40 before potentially advancing toward $10.36, while stressing that the projection is dependent on XRP breaking key resistance levels and attracting substantially greater market demand. A separate analysis from <a href="https://www.globenewswire.com/Tracker?data=VLkKxQl5GB45nUbvgZtWhq2Mvx1ULTj35bvVFXFe0KoZCpomcvuzOwsnBMEL9aiAThI-zXl39S3fdl428ndgs_QqbHP0SIbpTHC8YxKxj4MmFvz9ViLMQfu263oIOFVYijxpyQa6PDU-p-cZzdzGPb_wyXS_gnntrtTxUk7vX3D8Ew16ZL_bI6Ul-KCas4m2cuqSxBKW4ZIOQjEZDUEbGw==" rel="nofollow" target="_blank" title="">TradingKey</a> also examined whether XRP could reach $10 by 2030, highlighting institutional capital, adoption and the global payments market as potential long-term catalysts while acknowledging significant regulatory and macroeconomic risks. The $10 target is therefore far from a consensus near-term forecast. At current prices, XRP would need a substantial increase in both demand and market capitalization to reach that level. Yahoo Finance recently noted that a $10 XRP would imply a valuation of roughly $625 billion, illustrating the scale of the move required. Still, the fact that multiple analysts continue to model double-digit XRP scenarios has kept the target firmly within the crypto news conversation. Why Moonberg Is Appearing Alongside XRP XRP and Moonberg occupy very different positions in the market, but their appearance in the same conversation reflects a familiar crypto-market dynamic: traders looking at both established assets and projects that are still early in their lifecycle. XRP's $10 thesis depends on a major expansion in adoption, liquidity and institutional demand. On the flip side, Moonberg is attempting to establish itself before that kind of market recognition and price appreciation has been realized. Its $MBX presale has now crossed $300,000, while the project's trading terminal gives the token a utility narrative centred on AI-powered market intelligence and automation. That creates a potentially compelling early-stage proposition for traders who are willing to accept the considerably higher risks associated with presales. The attraction is also partly about timing. As each Moonberg allocation progresses, participants entering later may face different pricing from those who entered during earlier stages. If demand continues to build, the current $300,000 milestone could eventually look like an early chapter in the project's development, similar to that of XRP in the early days when holders saw the upside. Conclusion The XRP price prediction remains a highly debated topic, with some analysts identifying a potential path toward $10 if XRP benefits from stronger institutional adoption, liquidity and a broader crypto-market expansion. Moonberg is pursuing a much earlier opportunity. With its new crypto presale now above $300,000, the project is continuing to build momentum around $MBX while positioning its AI-native trading terminal within one of crypto's emerging narratives. For traders looking beyond the established names dominating today's crypto news, Moonberg's current presale stage offers an opportunity to enter the project before it reaches a larger market and later token-sale stages. Stage two is closing fast, and the next price increase will come around sooner rather than later. For more information about Moonberg ($MBX): <a href="https://www.globenewswire.com/Tracker?data=YatoejpICPPdJRmoc0bfuxt_HoEKlKGNf4UItMpU9K1P49XmTsOEw3YZk-3VAaya-GvbWz-sV3QbQUr4byfOevc3Pc6WR4ZtQ5jshLbq_SRxtUGn2poWZkDIOmKg7S_c" rel="nofollow" target="_blank" title="">Official Website</a> FAQs Can XRP reach $10? XRP could potentially reach $10 in a highly bullish long-term scenario, although it would require a substantial increase in demand and market capitalization. Several analysts have explored double-digit XRP targets, but they remain speculative. What is the new crypto presale Moonberg? Moonberg is a new crypto presale centred on $MBX and an AI-native trading platform combining market intelligence, on-chain analysis and AI-powered trading tools. Why are traders watching Moonberg early? Moonberg combines an early-stage token sale with an AI-focused trading ecosystem. As the presale progresses, later stages may carry different pricing, although participants should understand that crypto presales involve substantial risk. Disclaimer: This press release is for informational purposes only and does not constitute investment or legal advice. Cryptocurrency and crypto presale investments involve substantial risk, including the potential loss of the entire investment. Price predictions are speculative and are not guarantees of future performance. Readers should conduct their own research and seek independent professional advice before investing. <pre>CONTACT: MEDIA CONTACT
Contact: Barret Jacobs
Website: moonberg.com
Email: pr@moonberg.com</pre> <img alt="" src='https://ml.globenewswire.com/media/NTUzMzg5MjAtZjNiYS00YjIzLTgzZjYtMDQxOWYwMzBiNzRiLTUwMDE2NjQ3NS0yMDI2LTA4LTIxLWVu/tiny/Moonberg.png' referrerpolicy='no-referrer-when-downgrade' />

Crypto News: New Crypto Presale Moonberg Taps $300,000 As XRP Price Prediction Targets $10

Form 8.3 -DCC plc

To Nasdaq Copenhagen A/S                        21. August 2026                                         Announcement no. 71/2026 Final terms for bond admitted to trading 26th August 2026 On 26th August 2026, Jyske Realkredit A/S will be admitted to trading a new Covered Bond (SDO). Final terms for the bond are attached to this announcement. The full prospectus for the Bonds consists of the attached final terms and the previously disclosed ”Base Prospectus for the issue of Covered Bonds (SDO), Mortgage bonds (“RO”) and Mortgage Bonds (RO) and bonds issued pursuant to Section 15 of the Danish Mortgage-Credit Loans and Mortgage-Credit Bonds etc. Act (Section 15 Bonds).”, dated June 4th 2026. Jyske Realkredit’s base prospectus is available on Jyske Realkredit’s home page jyskerealkredit.com Yours sincerely, Jyske Realkredit Please observe that the Danish version of this announcement prevails. <a href="https://www.globenewswire.com/Tracker?data=pupQK_xGX2uy5cTtdr_nDPpVSIZZb5dukVQZmG8tsoDdGv4ecZ49-WFgrMAtQRR1n0hO0aWYmIeud5ctnw4Zrgw-yhGLkRkt94h_CrIiFWy0bnPdPqDbH7qxpsglOaNF" rel="nofollow" target="_blank" title="www.jyskerealkredit.com">www.jyskerealkredit.com</a> 


 Attachment

<ul id="gnw_attachments_section-items">
 <li>
 <a target="_blank" href="https://www.globenewswire.com/Tracker?data=HZ0J4g0sriKb2ibauqR12oUCUqsdEVtxu1VoXKq3PRq37lx4TkzPMBpjYwHEhYEFD6J2u9pso7rjVmqfbUyfjtRRC7frNI3mOxj3nd9-EPRmcUHb-4siZiKf_4dSJhAUszfDKYx9evrTqNKkXB41ZU0S1QW23oCk4w2fFE_AhIVb6lHXIn3XK5sQi68IvH512A7i-fGMqTByE5wJ4FC0np74fXHIbeXM4bl6E8WIuIE=" title="DK0009420655 - Final terms series GCB 3.25 321.E.EUR OCT31 RF" rel="nofollow">DK0009420655 - Final terms series GCB 3.25 321.E.EUR OCT31 RF</a>
 </li>
 </ul>
 <img alt="" src='https://ml-eu.globenewswire.com/media/OTA3NmI5M2YtZjcxNC00MWMzLTkyNzQtZDUxOTFlZDM2Yjk5LTExMDA1MDctMjAyNi0wOC0yMS1lbg==/tiny/Jyske-Realkredit-A-S.png' referrerpolicy='no-referrer-when-downgrade' />

Correction: Final terms for bond admitted to trading 26th August 2026

AS LHV Group announces that during the period 14 August to 20 August 2026, it has acquired the company’s own shares on the Nasdaq Tallinn Stock Exchange as follows:  <table style="border-collapse: collapse; width:452.25pt; border-collapse:collapse ;"><tr><td style="width:201px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Date </td><td style="width:201px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; ">Aggregated volume (pcs) </td><td style="width:201px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; ">Weighted average price per day (EUR) </td></tr><tr><td style="width:201px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; ">14.08.2026</td><td style="width:201px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; ">10,600</td><td style="width:201px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; ">3.335</td></tr><tr><td style="width:201px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; ">18.08.2026</td><td style="width:201px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; ">10,600</td><td style="width:201px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; ">3.345</td></tr><tr><td style="width:201px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; ">19.08.2026</td><td style="width:201px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; ">10,400</td><td style="width:201px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; ">3.34</td></tr></table>   LHV Group is acquiring its own shares based on the resolution of the company’s <a href="https://www.globenewswire.com/Tracker?data=2zI4HrA0m21p-UDXOqkL3fpnFTRBT5zPmhqZ_AteD2QEqIAj1aQpgZ4ZgKL2aI0P-Py7rk92EyqdBRNHQLWzSJCPtg0uwiFApz3LMkRja-NRf6itcq8tihcVeWObeziyQP8n3G9SrBYCHg05Ic5F-J3bnDqEYyFeE3u2eUFywaKCB4syCkf-MvWwJQHpVdhv" rel="nofollow" target="_blank" title="general meeting of shareholders held on 26 March 2025">general meeting of shareholders held on 26 March 2025</a>, and under the <a href="https://www.globenewswire.com/Tracker?data=BX3DQFkA3UvgJDzyDQjUuN_36WsNegLC-Hb_yQLB2cdfWbuScqRrLdkc6tWTug5ICVOJckshjN6IBMYf-qDVQJWz7JNbmkT1oT4rdGqR8DPlKQc5q95f0OpV4Hsu9KWfpxndp1e324aXu8Oy3K-t02Z7MiM-M8jVUtrl4Kw219U=" rel="nofollow" target="_blank" title="conditions decided by the Supervisory Board">conditions decided by the Supervisory Board</a>. The authorized agent for the transactions is AS LHV Pank. Summary data of the acquisitions will be disclosed no later than on the seventh trading day after the transaction and will be made available to the Financial Supervision and Resolution Authority, via the Nasdaq Tallinn system, and on LHV Group’s investor website.  LHV Group is the largest domestic financial group and capital provider in Estonia. LHV Group’s main subsidiaries are LHV Pank, LHV Varahaldus, LHV Kindlustus and LHV Bank Limited. The Group employs nearly 1,200 people. LHV’s banking services are used by more than 510,000 customers, LHV-managed II pillar pension funds have over 104,000 active customers and LHV Kindlustus provides insurance protection to 244,000 customers. LHV Bank, a subsidiary of LHV Group, holds a UK banking licence and offers banking services to international financial technology companies, loans to small and medium-sized enterprises and retail banking services.    Investor Relations  Sten Hans Jakobsoo  Head of Investor Relations and Corporate Development  Email: <a href="https://www.globenewswire.com/Tracker?data=UgaTBcHncUqGiYkOtqYeqvGLLgmvl8RHjC3oJcTqnVhpxN9UZl47JX59QQkEfYIZLA957W1OytkKDs_JtqxcEi8FcgD1A9HiMxBVCiH6LncNjOWCMegni220yJt8iZXITvOkXSaUoU4A3YU7U1fOJgjnROBfv_XfBIu4UrzHKPrmL9i7W3HaOBRdchXHzjFthQyhOUsv4BxFT3AuJijIohzO_5GCkYm16LuH7PDcEiT4cUCm2NrMwEisFoY_dsB2IUz16FVTjjCE9mWSnPeEV4LhwhPCpg0gP-h8FGOwdGl-dAz5j4Lepo-4xvndT_q4dwjYfZi2hNjXIUvWOlHqW1dZ5PxaywACPUGQV8wwFJWjK9owYEk7esGuM3iRu41lWJUrzb5jh3J0xhi-DC0qAhlT1LJDbRrYiJrp_50r310R6RsHwjtIt2jfExx5fjvH-EaeSSBKNtioYDPjZ1dAGMspHhAvBilNkKyzMpOBUMyutTtTtq3vP8ltMVFTwRMwLwlDYwuJgs3HKQwyInWrOA==" rel="nofollow" target="_blank" title="stenhans.jakobsoo@lhv.ee">stenhans.jakobsoo@lhv.ee</a>  Communications  Paul Pihlak  Head of Communications  Email: <a href="https://www.globenewswire.com/Tracker?data=D5waUxJWf-1eEpHoPzLqleH-iKP9H84Fvejvc8KrQvBUtB_GcTptywrQV0EFhqA5FUA6T5tT3aV3uiEko4C0wkcd9cZ2wP0ITnXEl51MzI3OnonhgfyBOnd_hCgOEl-R5GzwzJac6P8CdPc3HYJmPvP9e10X0tPgRFM7bDwbA9NixLLjdZNCxZWA0Uu3xFaP2lDsYkCOKhmzT1Z3qDhd2AKDy-vvuFe5mgG5zuUJED6PuN5TKxMIZUMd4-wmH8Rp6R_Oq8DMtwrkTLhaxAwROgmIb4Tm9utmpSwX3ZLly8r7_KKUf0IV0klza6nGUyFEE5PP88sV4VJhaFs-WoxohkdF7j55EBf8gYQDpIAyCc_kIGAuODHuWYhtuqNoq7O2xnESNcaHr7CvzKUNvqmAkwvL3y48qTLNaCAKvd2DqFppve6GALI5Keyg88upxc2mwham7X981YQkK-t9n-5bGMPcXbAOJVwHWCyAwVlWg0DSH-vPgTzoMQ2zqCbEJCFg" rel="nofollow" target="_blank" title="paul.pihlak@lhv.ee">paul.pihlak@lhv.ee</a>   <img alt="" src='https://ml-eu.globenewswire.com/media/MTIzY2VmZjQtOTQxMi00YmZmLWIzNjctM2I1N2ZkNDlhMDI3LTExMDc1OTctMjAyNi0wOC0yMS1lbg==/tiny/AS-LHV-Group.png' referrerpolicy='no-referrer-when-downgrade' />

LHV Group's own share acquisition transactions 

<img alt="The F1® Allwyn Global Community Award 2026 trophy presented to Monique Maks (Director) and Ronald de Boer (former footballer and ambassador) of winnin" height="600" src="https://ml-eu.globenewswire.com/Resource/Download/d0d27a4e-6a34-4a3b-ba6d-50db4fce8919/the-f1-allwyn-global-community-award-2026-trophy-presented-to-monique-maks-director-and-ronald-de-boer-former-footballer-and-ambassador-of-winning-local-charity-spieren-voor-spieren-at-the-formula-1-he.jpeg" width="400" data-dpi="96" data-caption="The F1® Allwyn Global Community Award 2026 trophy presented to Monique Maks (Director) and Ronald de Boer (former footballer and ambassador) of winning local charity Spieren voor Spieren at the FORMULA 1® HEINEKEN DUTCH GRAND PRIX 2026 in the Netherlands." data-filename="The F1® Allwyn Global Community Award 2026 trophy presented to Monique Maks (Director) and Ronald de Boer (former footballer and ambassador) of winning local charity Spieren voor Spieren at the FORMULA 1® HE.jpeg" /> The F1® Allwyn Global Community Award 2026 trophy presented to Monique Maks (Director) and Ronald de Boer (former footballer and ambassador) of winning local charity Spieren voor Spieren at the FORMULA 1® HEINEKEN DUTCH GRAND PRIX 2026 in the Netherlands. ZANDVOORT, Netherlands, Aug. 21, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- Spieren voor Spieren has been named the Dutch winner of the F1® Allwyn Global Community Award at the 2026 FORMULA 1 HEINEKEN DUTCH GRAND PRIX. The non-profit, which works to transform the lives of 20,000 children with muscular diseases in the Netherlands, has been awarded €100,000 from Allwyn, the multi-national lottery-led entertainment company. The judges were impressed by how Spieren voor Spieren uses sport to promote inclusion and long-term positive change. The full €100,000 donation will support the 2026 Spieren voor Spieren Day on 30 August; an annual event for 600 participants, where children with muscle diseases and their families can safely enjoy sport, play and new experiences. In the Netherlands, 20,000 children battling muscular diseases face the daily loss of mobility and independence, whether that’s walking, playing or breathing independently. Spieren voor Spieren - which also visits Formula 1® race weekends annually with its young ambassadors - changes this reality by accelerating research, improving access to earlier diagnoses and innovative treatments, and investing in sport and physical activity programmes that help children with muscular diseases stay active. The Spieren voor Spieren Day, which will be bolstered and expanded by the donation, is an annual event that brings together hundreds of children and their families to push their limits, play sports, climb, dance, make new friends, and meet elite athletes. Themed Everything Upside Down – in celebration of unexpected moments and new experiences – it provides a day like no other, filled with joy, energy and empowerment. Spieren voor Spieren’s relationship with Formula 1® will continue to make a lasting impact through this Award. Several of the foundation’s young ambassadors, children living with muscular diseases, attend a race weekend annually with their families. For these children, whose daily routines are often dictated by medical treatments and physical challenges, the track offers a rare escape: a day defined not by limitations, but by speed, spectacle and the opportunity to be part of the global Formula 1® community. Aleš Veselý, CEO of Allwyn Czechia and F1® Allwyn Global Community Award judge, said: "Spieren voor Spieren’s mission perfectly embodies the Award’s focus of empowerment and inclusion, creating an environment where children and their families can experience genuine connection with others facing similar challenges. The combination of sport, family engagement and community building makes the project highly visible, emotionally compelling, and strongly aligned with the spirit of the F1® Allwyn Global Community Award." Ellen Jones, Head of ESG at Formula 1® and F1® Allwyn Global Community Award judge, added: "At Formula 1® we recognise that sport has the unique power to inspire and connect children, families, and communities. We are proud to award Spieren voor Spieren this accolade because its initiative perfectly embodies our commitment to inclusion, ensuring that everyone has the opportunity to participate and thrive in the sporting experience." Monique Maks, director of Spieren voor Spieren, said: "We're incredibly proud and grateful to receive the F1® Allwyn Global Community Award. Every day, 20,000 children in the Netherlands live with the effects of a muscle disease. We stand beside them during the biggest challenge of their lives, but it's a challenge we can't overcome alone. Because this is about more than medical breakthroughs — being part of everyday life matters just as much. This Award makes that possible for at least one day during our annual Spieren voor Spieren Day." Ronald de Boer, ambassador for Spieren voor Spieren, added: "As a former professional footballer, I know what it means to fight for something. But while I fought for titles and trophies, these kids fight every day just to keep up. That takes enormous determination. So to me, these kids embody the true meaning of fighting spirit. We celebrate that spirit every year at the Spieren voor Spieren Day. And this award means we can keep doing exactly that." Spieren voor Spieren is the fourth non-profit to be recognised by the F1® Allwyn Global Community Award in 2026, following the British Starlight Children’s Foundation; Canadian charity La Tablée des Chefs; and Austrian non-profit Sindbad Mentoring. More organisations will be recognised across the Grand Prix race locations this season in Austin, Mexico City and Las Vegas. Later in the year, Formula 1® fans will have the chance to cast their vote on their favourite winning initiatives as part of Allwyn’s plan to bring these fans closer to the programme. Notes to editors About Allwyn Allwyn AG is a multi-national gaming entertainment company, lottery-led and with leading market positions and trusted brands across Europe and North America, listed on Euronext Athens. Its purpose is to make play better for all by focusing on innovation, technology, player safety and returning more to good causes across a growing casual gaming entertainment portfolio. About Allwyn’s partnership with Formula 1® The multi-year partnership with Formula 1® represents a drive towards increased global awareness for Allwyn, with the sport’s 24 races across the globe, 750 million fans, and 96 million social media followers, as well as its reach across broadcast channels and entertainment outlets. The partnership will reinforce Allwyn's position as an international brand driving community impact across the world, in support of its global growth plans. At the heart of the partnership is the development of initiatives that will support the company’s ambition to be a positive contributor to society globally. With Allwyn and Formula 1® equally committed to empowering fans and local communities, the partnership will give Allwyn the opportunity to utilise the sport’s ever-growing international fan base to celebrate those making positive change, sharing these inspiring stories on a global level. About Formula 1® Formula 1® racing began in 1950 and is the world’s most prestigious motor racing competition, as well as the world’s most popular annual sporting series. Formula One World Championship Limited is part of Formula 1® and holds the exclusive commercial rights to the FIA Formula One World Championship™. Formula 1® is a subsidiary of Liberty Media Corporation (NASDAQ: FWONA, FWONK, LLYVA, LLVYK) attributed to the Formula One Group tracking stock. The F1 logo, F1 Formula 1® logo, Formula 1®, F1, FIA FORMULA ONE WORLD CHAMPIONSHIP, GRAND PRIX, PADDOCK CLUB and related marks are trademarks of Formula One Licensing BV, a Formula 1® company. All rights reserved. Further information about the F1® Allwyn Global Community Award, including eligibility criteria and the selection process, can be found on our website: <a href="https://www.globenewswire.com/Tracker?data=GuYBjrmefprQijyxcO1EZO_kR7T_IPtOZ-ssc3RBI0-CQKl8_bKmlmjq_UCi_W8NnL1bqYHSPKjh2F7SkLztRXnpw8ad2K2p-wV61raKlRUXg4xJd2rjBnxQ4N79pys1VVW5gRhAxBEvOcuhK6tkavOUCSTbPFSDxwIyx7P1mouw1R1ynFnlgj09ohEofljn" rel="nofollow" target="_blank" title="">https://www.allwyn.com/responsibility/community-award</a>. About Spieren voor Spieren Spieren voor Spieren is a Dutch non-profit organisation committed to improving the lives of approximately 20,000 children living with muscle diseases in the Netherlands. The organisation supports research, earlier diagnosis and the development of new treatments, while also creating opportunities for children to participate in sport and physical activity. Through its programmes and partnerships, Spieren voor Spieren helps children and their families stay active, build connections and enjoy experiences that might otherwise be inaccessible to them. A photo accompanying this announcement is available at <a href="https://www.globenewswire.com/Tracker?data=GuYBjrmefprQijyxcO1EZHIxhOfvCCCnC04NfG_r3YgCMm8_B-elJS2zNhFoTw45MyVd4SmDN1rZp8YDjtkPEltpy5sGAEPWnQNOME7Q336cDyISm4ef6ezTfjacDmSNh0hMr9Wksx0jnTdaUccK1vGzLCqyJvjbgY1Xt3UKZC168vXN70tzyOJAkG_PuynBqPg34S73IUsSyjgzlFjtbA-itM8-yw0ELpJ9FvuSVX6Gn4gzUD-96j6uGPcnY_lYkmpG0vNb_N_OueQn18GFxg==" rel="nofollow" target="_blank" title="">https://www.globenewswire.com/NewsRoom/AttachmentNg/d0d27a4e-6a34-4a3b-ba6d-50db4fce8919</a> <pre>CONTACT: Media enquiries pr@allwyn.com

Press contacts

Formula 1® Press Office

E: f1media@f1.com

T: @f1media</pre> <img alt="" src='https://ml-eu.globenewswire.com/media/ZDJhNWU1NDEtZmVmMi00OGI3LWI3YjctODM3MDE1YmE2ZjU2LTcwMDAyNjExMi0yMDI2LTA4LTIxLWVu/tiny/Allwyn.png' referrerpolicy='no-referrer-when-downgrade' />

Spieren voor Spieren wins Dutch F1® Allwyn Global Community Award to transform lives through adaptive sport

Form 8.3 - Gooch & Housego plc - Octopus Investments

Form 8.3 - Advanced Medical Solutions Group plc - Octopus Investments

New energy group EPSO-G (legal entity code 302826889, registered office address: Laisvės pr. 10, Vilnius, Lithuania) announces interim financial and operating results for January–June of 2026. Key financial indicators for the first six months of 2026: <table style="border-collapse: collapse; border-collapse:collapse ;"><tr><td style="width:304.54px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Key financial indicators</td><td style="width:103.94px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; ">January-June 2026</td><td style="width:104px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; ">January-June 2025</td><td style="width:104px;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; ">Change, %</td></tr><tr><td style="width:304.54px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Revenue, EUR million</td><td style="width:103.94px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">327.8</td><td style="width:104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">257.6</td><td style="width:104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">27.3</td></tr><tr><td style="width:304.54px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">EBITDA, EUR million</td><td style="width:103.94px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">80.8</td><td style="width:104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">-29.2</td><td style="width:104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">n/a</td></tr><tr><td style="width:304.54px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Net profit, EUR million</td><td style="width:103.94px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">55.1</td><td style="width:104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">-41.3</td><td style="width:104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">n/a</td></tr><tr><td style="width:304.54px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Investments in energy infrastructure, EUR million</td><td style="width:103.94px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">99.6</td><td style="width:104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">83.3</td><td style="width:104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">19.6</td></tr><tr><td style="width:304.54px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">ROE (last 12 months), %</td><td style="width:103.94px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">32.6</td><td style="width:104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">-5.0</td><td style="width:104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">n/a</td></tr><tr><td style="width:304.54px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Net debt, EUR million</td><td style="width:103.94px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">27.8</td><td style="width:104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">87.7</td><td style="width:104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">-68.3</td></tr><tr><td style="width:304.54px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Adjusted* EBITDA, EUR million</td><td style="width:103.94px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">44.1</td><td style="width:104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">40.5</td><td style="width:104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">8.7</td></tr><tr><td style="width:304.54px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Adjusted* net profit, EUR million</td><td style="width:103.94px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">24.4</td><td style="width:104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">17.7</td><td style="width:104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">37.6</td></tr><tr><td style="width:304.54px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Adjusted* ROE (last 12 months), %</td><td style="width:103.94px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">11.8</td><td style="width:104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">12.3</td><td style="width:104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">n/a</td></tr><tr><td style="width:304.54px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Adjusted EBITDA (last 12 months), EUR million</td><td style="width:103.94px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">80.3</td><td style="width:104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">75.4</td><td style="width:104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">6.5</td></tr><tr><td style="width:304.54px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; ">Net debt-to-adjusted EBITDA (last 12 months)</td><td style="width:103.94px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">0.3</td><td style="width:104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">1.2</td><td style="width:104px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">n/a</td></tr></table> * Profitability indicators are recalculated due to temporary regulatory deviations from the regulated profitability approved by the National Energy Regulatory Council. When calculating adjusted indicators, the adjustment of revenue for previous periods, which has already been approved by the NERC decision when setting regulated prices for transmission services for the reporting period, is taken into account and the deviation between the (regulated) profitability approved by the NERC and the actual profitability for the reporting period is assessed, which will be evaluated by the NERC when setting transmission prices for future periods. Other atypical gains or losses are also eliminated when calculating the adjusted indicators. EPSO-G group of companies consists of the holding company EPSO-G and six directly controlled subsidiaries: Amber Grid, Baltpool, Energy cells, EPSO-G Invest, Litgrid and Tetas. EPSO-G and the Group companies also hold shares in Rheinmetall Defence Lietuva, Baltic RCC OÜ and TSO Holding AS. The Ministry of Energy of the Republic of Lithuania exercises the rights and obligations of the sole shareholder of EPSO-G. Enclosed: Integrated Interim Report for the first six months of 2026 (management, consolidated and company financial statements) and press release. Further information Gediminas Petrauskas, Communications Partner at EPSO-G Tel. +370 610 63306, email<a href="https://www.globenewswire.com/Tracker?data=Y3l9oZEW6sVScaxwbOGlOYTMyr7EPkIR5CBHTKsJwRZxWuPnt4Ry0meSS3-oCYbLfLdsk-SEni6Kmj-MTrx8w0tUUpStfU306uyc6S-aFXLZNhZLAX2R-x_NyJ_vWS5rL40uOUXkmOP2bQ7EqhhGcIFwHsEMz5P1yequE5ILYrxdpNNzKT2nr-Mt6O6kDQ9_nX18du5JtSkXkToVpcU6uY1aOEQwyv9SK8Ek9YGLEDMniSL0vCFR1JMPnpafGfuv7oUI1tC18F57tKddF5lSQOa4lTpwCOjudQPziz4BuBzpcHX3o69IdcL3bVPYgKusunt3uW8AnEUsAl9ev3Y7kQw277gDIBUqO7YSD-xGWuG0EUcYGubb7YJdxgtujvqhFb5Y7BVE_nGdKcb9sv7WQVZF5vG0KfAkIuwmtiECe292sY_QEA5DDPitVty4wvfOcEVMGXdprsrvHw2jIciuQEk2qqBSUue8Q519l7zYALsjCxl0MB3lVwrTd0MrO3g9xURQAx9BxdaoUiOhDUNRydhjBrFCqO3fKQF5wmKHkBtlPGyGFqiZUyYqUg18bMVDm2jjjl1qgm8qMrFvcWmAiP9AeC_H4KjvsVWYq3vOAEVuUy6WNLRJnhVNf3mZcB2nH2WcQ-JSLAT-bkF_6AlJc8T5YQBAVW0FgDb2KxXtqGhVQ-69dO6yb-JY_IWkSKmL0xSAS-d5nLh3s-7Vt6DT1DhaipVjAe4H6KBFboJrKhi-N5MCB6TwfX9UZENHCiO2cKtQqW2cK_wrNM_b5yu_td7iU5Tq1pEIZU_leAE6VTP2cck0SMIFPBPFSK-iRZKXroug3GcNwQlWrq8ZKmqvYIPU0Istto2pcFQ7NQ1Z9_shfafCJzOKeSFVcXM49noDSQbQlPIRwbQgUVHRrsq1Aw==" rel="nofollow" target="_blank" title=" gediminas.petrauskas@epsog.lt"> gediminas.petrauskas@epsog.lt</a> 
 Attachments

<ul id="gnw_attachments_section-items">
 <li>
 <a target="_blank" href="https://www.globenewswire.com/Tracker?data=febHfmuIqPbSoxFGz5_5FyNq8I8RC6a_mTEUkVe2M4LovAmsBk4OWYU2dlF5hWhPVLa4h4U-RCEE9dB-WLtaAsKg6RmE_pvH_Gp8srzsTH2fKCq9Wm7NFJgAqvx9UotsZwro2Q0YYuwWkU_UcIu_izOQtA1uBUawOGh1r8hXAIdGUT7cbJiayLUJapoDFDoleWXGfnL1lETzsQvlEnhhzA==" title="2026-08-21_EPSO-G_Group_results_H1_2026" rel="nofollow">2026-08-21_EPSO-G_Group_results_H1_2026</a>
 </li>
 <li>
 <a target="_blank" href="https://www.globenewswire.com/Tracker?data=eU-6ZMumf1Z_tZGug0Ixl3v3qgnSsQ_wcD_EN3NibrV6_hXUpdyt_HymAnybRxPBW5SkQ3Yn97BUkIgKR-utYMYQY5g2MbXDgLPI-Q37RYmJFd4nxGYEPKDfpkQgDom1tW5NNHsZl7NCfpZuf3BwMn9J5-Rm5x_LpgghhHsjxa3S9J3iNEmO_T_-sCxhEeZS" title="EPSO_G ataskaita 2026 ENG" rel="nofollow">EPSO_G ataskaita 2026 ENG</a>
 </li>
 </ul>
 <img alt="" src='https://ml-eu.globenewswire.com/media/NWExYmE0NWUtOWE2NC00OWM4LWJmYWEtOTM0YjFjNzNiNjhhLTEyNjAyMzUtMjAyNi0wOC0yMS1lbg==/tiny/EPSO-G-UAB.png' referrerpolicy='no-referrer-when-downgrade' />

EPSO-G group announces financial results for the first six months of 2026

Frontline plc.’s preliminary second quarter 2026 results will be released on Friday August 28, 2026, and a webcast and conference call will be held at 3:00 p.m. CEST (9:00 a.m. U.S. Eastern Time). The results presentation will be available for download from the Investor Relations section at www.frontlineplc.cy ahead of the conference call. In order to attend the conference call you may do one of the following: a. Webcast Go to the Investor Relations section at www.frontlineplc.cy and follow the “Webcast” link, or access directly from the link below. <a href="https://edge.media-server.com/mmc/p/uizx3ocs" rel="nofollow" target="_blank" title="Frontline plc Q2 2026 Webcast">Frontline plc Q2 2026 Webcast</a> b. Conference Call Participants will need to register online prior to the conference call via the link below. Dial-in details will be available when registered.              <a href="https://register-conf.media-server.com/register/BI81c923ce7b3349db847fc350aa34270d" rel="nofollow" target="_blank" title="Frontline plc Q2 2026 Conference Call">Frontline plc Q2 2026 Conference Call</a> A Q&amp;A session will be held after the teleconference/webcast. Information on how to submit questions will be given at the beginning of the session. The presentation material which will be used in the teleconference/webcast can be downloaded from www.frontlineplc.cy This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. <img alt="" src='https://ml-eu.globenewswire.com/media/MWU5YTBlOTUtMGQ1Yi00ZjYxLWJmNDItZWYwMWQ4NWQ1ZjIwLTEwMTQ5NTEtMjAyNi0wOC0yMS1lbg==/tiny/Frontline-plc-.png' referrerpolicy='no-referrer-when-downgrade' />

FRO – Invitation to Q2 2026 Results Conference Call and Webcast

To Nasdaq Copenhagen A/S                        21. August 2026                                         Announcement no. 71/2026 Final terms for bond admitted to trading 26th August 2026 On 26th August 2026, Jyske Realkredit A/S will be admitted to trading a new Covered Bond (SDO). Final terms for the bond are attached to this announcement. The full prospectus for the Bonds consists of the attached final terms and the previously disclosed ”Base Prospectus for the issue of Covered Bonds (SDO), Mortgage bonds (“RO”) and Mortgage Bonds (RO) and bonds issued pursuant to Section 15 of the Danish Mortgage-Credit Loans and Mortgage-Credit Bonds etc. Act (Section 15 Bonds).”, dated June 4th 2026. Jyske Realkredit’s base prospectus is available on Jyske Realkredit’s home page jyskerealkredit.com Yours sincerely, Jyske Realkredit Please observe that the Danish version of this announcement prevails. <a href="https://www.globenewswire.com/Tracker?data=yb01J4Kh0Hn8lAUI54sXvR-tHuxd5WPMpIrONpH6WrY316N_R7MqAtReRXtpc6sL7jBE70HY8KuJOau6v3RuEBFvCAohFENGVFoh1XzTn92xJ-J90MqtoI3XxC6xw-Jk" rel="nofollow" target="_blank" title="www.jyskerealkredit.com">www.jyskerealkredit.com</a> 
 Attachment

<ul id="gnw_attachments_section-items">
 <li>
 <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pPURzFM7geHeDB3Uw_51l4gMK_mHBje43ViLI5UiMkrDPrFayymgiXr5kvT7T613hOwGTjdh7B4ouabXbTdaOWZIxSRiuiMf5HebaXcO83ncz27easDAfcyAe9Lu5EH7r0p7SYybs_-mlvdHjfodRl3YmrSa4B0Gc7tRkKA8hgo4B-ynMO8Au2SvcIKVHuPBQNBHePl1WiJ7S4A_UOqKPORuafVrOr-Eh6k4iL0qLyY=" title="DK0009420655 - Final terms series GCB 3.25 321.E.EUR OCT31 RF" rel="nofollow">DK0009420655 - Final terms series GCB 3.25 321.E.EUR OCT31 RF</a>
 </li>
 </ul>
 <img alt="" src='https://ml-eu.globenewswire.com/media/YTFhNmZiNjUtYmQ4NC00NTY4LTk0YzctNTIyOGNjZjYxMDE1LTExMDA1MDctMjAyNi0wOC0yMS1lbg==/tiny/Jyske-Realkredit-A-S.png' referrerpolicy='no-referrer-when-downgrade' />

Final terms for bond admitted to trading 26th August 2026

REYKJAVIK, ICELAND (August 21, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical (TWSE Stock Code: 1795) covering two of Alvotech’s candidates in the United States and selected Asian markets: AVT34, a proposed biosimilar to Imfinzi® (durvalumab), and AVT87, a proposed biosimilar to Hemlibra® (emicizumab). Imfinzi® is an oncology biologic used in the treatment of multiple cancers, which generated global sales of approximately $6.1 billion in 2025¹. Hemlibra® is a biologic for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A that generated global sales of approximately CHF4.8 billion (approximately $5.8 billion) in 2025². Under a semi-exclusive agreement in the United States, Alvotech retains the right to commercialize both products directly alongside Lotus, while Lotus will commercialize the products through Alvogen, its U.S.-based wholly owned subsidiary. Alvotech will retain responsibility for product development, and for obtaining and maintaining marketing authorizations in the United States, and will serve as the exclusive supplier of the products for all markets. In Asia, Lotus will have exclusive commercialization rights in eight selected markets: South Korea, Taiwan, Thailand, Vietnam, the Philippines, Singapore, Hong Kong and Malaysia. Lotus will be responsible for local regulatory submissions and commercialization in these markets. The agreement has a potential value to Alvotech of up to approximately $150 million in upfront and milestone payments, in addition to ongoing revenues from the supply of commercial product. “This agreement represents an important evolution of Alvotech’s commercial strategy,” said Lisa Graver, Chief Executive Officer of Alvotech. “For the first time, we will have the opportunity to participate directly in the future commercialization of our products in the United States, allowing us to retain a greater share of the value we create through our development and manufacturing platform. At the same time, our partnership with Lotus extends the potential reach of these two important pipeline assets across key Asian markets. We look forward to working together to bring these medicines to patients and broaden access to high-quality biologics.” “We are pleased to partner with Alvotech on two important biosimilar candidates that meaningfully advance Lotus’ global growth strategy,” said Petar Vazharov, Chief Executive Officer of Lotus. “By combining Alvotech’s integrated biosimilar development and manufacturing capabilities with Alvogen’s established U.S. commercial platform and Lotus’s deep market presence across Asia, we are building a strong foundation for the future commercialization of AVT34 and AVT87 across key global markets. These candidates expand the scale and reach of our biosimilar portfolio in oncology and rare diseases, and reinforces our commitment to broadening access to high-quality medicines.” Imfinzi® and Hemlibra® are registered trademarks and the property of their respective owners. 1)   AstraZeneca PLC. (2026). Annual report on Form 20-F for the fiscal year ended December 31, 2025. U.S. Securities and Exchange Commission. <a href="https://www.globenewswire.com/Tracker?data=UlZd3jiwSzUhivq327IzqtOxiXoRQQIMQVmwHiItdLXp7u7kjPhZ_bcrKmOgmEbB2N5a48sbs3POD1fzG_ljFN-Cci6znuLAzDxuG-wCiQQpX9qqJV69kFxBgpewUAjm85RVhEheTZTaWo3qbAf_5TfeB2G8bmljPSQtGppW5-vUEiHMQbTnDgItH6YwZuRp31Hi6FtfRapiWi9-xtDbJC1gotOCitkfZ2paAbWDRM3mWNFEV8giv6peKm9LxY8bYjRQ51sHqxRQNh8N67dteg==" rel="nofollow" target="_blank" title="">https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231x20f.htm</a> 2)   Roche, Finance Report 2025, F. Hoffmann-La Roche Ltd,       <a href="https://www.globenewswire.com/Tracker?data=UlZd3jiwSzUhivq327IzquVhU_SIQXoA7U293iKDDwCpP9jdCtIaNQTnCmQzbYeAeWhuq2mXwYjXCExYh3bdHYbCoXJM26QODg6nKXO57Eq5sdyhTM_eldkfJN7EYhz6ULoyC73covnnKJ2RFhhP1WRZ3jReV1IIs9gRYoeMR8BGjCtJIDIb74HvsPjZhJA-" rel="nofollow" target="_blank" title="">https://assets.roche.com/f/176343/x/fca190f63e/fb25e.pdf</a> Contacts Media contacts – <a href="https://www.globenewswire.com/Tracker?data=VpWQxqOUAJuickZffExt9C9fAREMXm1pZezqxeO22Cybf3rY3kvSYT4RZmiCgXJ9ehA7m21yf4TUh1FXLk1pzGV8iShhTxtn_ANFWTPOBAOvz-DC9T3EAm5mSqxfhjF7" rel="nofollow" target="_blank" title="">alvotech.media@alvotech.com</a> Benedikt Stefansson Sarah MacLeod Investor Relations contacts – <a href="https://www.globenewswire.com/Tracker?data=VpWQxqOUAJuickZffExt9MsAsi_mgXe8ngoIj7LuGJHYPICAB0oSE7Edi5SaNXoVlDhvef46vycljXY1CodVzy1d0bCT0dnTm7VciKRVAj_69FLYDDwAogud_r53sGGU" rel="nofollow" target="_blank" title="">alvotech.ir@alvotech.com</a> Dr. Balaji V Prasad Benedikt Stefansson About Alvotech Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release. For more information, please visit our  <a href="https://www.globenewswire.com/Tracker?data=ONMvbIBgaTwnQox17Ad086ZitUgBCdW6AhEP-Ed5L9bAdLoCheTpZX3bzMWd1v_rwukuyby5l1-7YlT-7UOa683XWlCINVgWZTNj2hK9_UPXtBIck5D77cchwMM2KjuYyeux2WCm23LpZoA1KFhBo7MLd1dtmv-yX-jzr495Y5Se0Ur1KvvdrmikNYIcwlH8KrbPO104bYI3ExfBb5XdA-rvlvXe4kSlAvbjTgo-nZQ=" rel="nofollow" target="_blank" title="website">website</a> or follow us on social media on <a href="https://www.globenewswire.com/Tracker?data=CzqC7LCqmyhGmGdBKMMYq6N78rHaakWjE0gbYXsAPemgKmbxcZnpP3dhZBSgPIR_saegYbEuXgsq5XWS6j8GqC1nU5ckvQfo3HxB1wrHl25MZ-feZbQcxuWUabFtglt29_PlnSNNV6PiRcJGaFLIYZ0ej3LmUUH8-9g7tNZToy-9CJKMkGUoRcHErNtHFKLMmcHHFbE6CEWDmtbE0fQglnerK-8djiz9JWIGW3b22yrgCyvXrA508qG78Mo0JnMY" rel="nofollow" target="_blank" title="LinkedIn">LinkedIn</a>, <a href="https://www.globenewswire.com/Tracker?data=2YYSQaRcSky43ZGRKHdFBcpO82XASxPvaNs49Drf8BqZd-HfJmY9CU46BNULm4A1qJi4w2I1fTGIsmVcGFP3WVNi1V4A8kf6-DWC_pgZDWMN6-BLW_8LheTiwijUcGKJB3Bygre4qDMcAyhTs5Qc7Uy_RFcj3zCTjTfJm_bbGdHST1hpvTU-tc9-qLgLEO_o5SvcozPKBLguT5TIIrNLi6m_dzuIBFgz6XHaeIJqmYpXcllGa6GOYBaosr9hfAl7" rel="nofollow" target="_blank" title="Facebook">Facebook</a>, <a href="https://www.globenewswire.com/Tracker?data=k7i9jeqW1ywHHXf5DkBLdArqWdkUbclQvmGqgvPs220UirafzAYDNGSrJFFjw5OKWpyjXcL4Rf0mMBD4Lt18RiV38DPIsTTDwSGKcxHTkA9uNyzxi7ZxSrw_gp6YAURV_mqv4FLHXgkGRzpFGNLqq5DM1OfPniQ9MOhCVVdK37-Aidq_-qGbwKrmLwh_DaHaYNWaYav-yunox1xsXpRMaWmef62KB5iSyTGGlgmHn2yGYmZWGBXuoYKWenPhWehb" rel="nofollow" target="_blank" title="Instagram">Instagram</a>, and <a href="https://www.globenewswire.com/Tracker?data=4ZYmpQC67y6ixxsIDv5BHGiA2KlyAo0oCsaVXlm7YK6oSX0Hy45ohCq9TcGfGUCVDMXSPautWoZY3oft2vvT7hLIfRzusMwq39lEzifoutDCBzyQCb2KkgxlD_rULBPOZS34m6I0643ErDLXt6ZGuBc5m9BRJ7gBWwtue3ZT5d8XfMrmxRdJzsZDAJLsMfuLCu2M9t9nVeCu4JG_x4o0Uxp6bQsCfgJ2Am1-cXi9pUD-6GIvUDaJXBtgAaxin9My" rel="nofollow" target="_blank" title="YouTube">YouTube</a>. Forward Looking Statements Certain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, for example, Alvotech’s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, market launches and financial projections. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time-to-time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed. <img alt="" src='https://ml-eu.globenewswire.com/media/MzhmODBmOWYtNTlkMi00NTA4LWJhMWQtZTFkYTY3OTFmYzA3LTEyNDUzODYtMjAyNi0wOC0yMS1lbg==/tiny/Alvotech.png' referrerpolicy='no-referrer-when-downgrade' />

Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets

REYKJAVIK, Iceland, Aug. 21, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical (TWSE Stock Code: 1795) covering two of Alvotech’s candidates in the United States and selected Asian markets: AVT34, a proposed biosimilar to Imfinzi® (durvalumab), and AVT87, a proposed biosimilar to Hemlibra® (emicizumab). Imfinzi® is an oncology biologic used in the treatment of multiple cancers, which generated global sales of approximately $6.1 billion in 2025¹. Hemlibra® is a biologic for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A that generated global sales of approximately CHF4.8 billion (approximately $5.8 billion) in 2025². Under a semi-exclusive agreement in the United States, Alvotech retains the right to commercialize both products directly alongside Lotus, while Lotus will commercialize the products through Alvogen, its U.S.-based wholly owned subsidiary. Alvotech will retain responsibility for product development, and for obtaining and maintaining marketing authorizations in the United States, and will serve as the exclusive supplier of the products for all markets. In Asia, Lotus will have exclusive commercialization rights in eight selected markets: South Korea, Taiwan, Thailand, Vietnam, the Philippines, Singapore, Hong Kong and Malaysia. Lotus will be responsible for local regulatory submissions and commercialization in these markets. The agreement has a potential value to Alvotech of up to approximately $150 million in upfront and milestone payments, in addition to ongoing revenues from the supply of commercial product. “This agreement represents an important evolution of Alvotech’s commercial strategy,” said Lisa Graver, Chief Executive Officer of Alvotech. “For the first time, we will have the opportunity to participate directly in the future commercialization of our products in the United States, allowing us to retain a greater share of the value we create through our development and manufacturing platform. At the same time, our partnership with Lotus extends the potential reach of these two important pipeline assets across key Asian markets. We look forward to working together to bring these medicines to patients and broaden access to high-quality biologics.” “We are pleased to partner with Alvotech on two important biosimilar candidates that meaningfully advance Lotus’ global growth strategy,” said Petar Vazharov, Chief Executive Officer of Lotus. “By combining Alvotech’s integrated biosimilar development and manufacturing capabilities with Alvogen’s established U.S. commercial platform and Lotus’s deep market presence across Asia, we are building a strong foundation for the future commercialization of AVT34 and AVT87 across key global markets. These candidates expand the scale and reach of our biosimilar portfolio in oncology and rare diseases, and reinforces our commitment to broadening access to high-quality medicines.” Imfinzi® and Hemlibra® are registered trademarks and the property of their respective owners. <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:4%; width:4%; min-width:4%;;text-align: center ; vertical-align: middle; vertical-align: top ; ">1)</td><td style="max-width:96%; width:96%; min-width:96%;;text-align: left ; vertical-align: middle; vertical-align: top ; ">AstraZeneca PLC. (2026). Annual report on Form 20-F for the fiscal year ended December 31, 2025. U.S. Securities and Exchange Commission. <a href="https://www.globenewswire.com/Tracker?data=Jf0UJ7nZarP9xcORhZN1aTbnRqkqRXuyxkOWYjXtsRe_urjzbb-3uaA0o_QcbR6ZdQ8dfOzjjZYJe8fwz5kv9m_rAiPoIN6oxLndjWSkpCi3gcQKEip5zH0K4hqDU8xYb04hIDa-5Co9VEb2okwOa8Ps3csZ32tmknN0UQHEgiiaq3dVuyx2ZvIjfPqPfNNaF96CG8UORoPRoWtNKCL7N1xl9t0sVwjpWbdoX_A3i4jR5nd3-i-zmOJ_Di5nFmQES0rimOGDQZNElVT0yBpTtw==" rel="nofollow" target="_blank" title="">https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231x20f.htm</a></td></tr><tr><td style="text-align: center ; vertical-align: middle; vertical-align: top ; ">2)</td><td style="text-align: left ; vertical-align: middle; vertical-align: top ; ">Roche, Finance Report 2025, F. Hoffmann-La Roche Ltd, <a href="https://www.globenewswire.com/Tracker?data=Jf0UJ7nZarP9xcORhZN1aRIdk2XWOlC7kxwuZMpaQ7bodkDDpVFwT41npskadV-zjISPekZPzJh2TPpDiFOMlaB5427mAsBrjarLG_iBFUMexQH9JxBfvVYN8VgcGPzZZNTULbcLwVvEz-2O2uheYdNPIoGD7pFoLYSCm-ahoWaOtFpoXA9ugVW-es3qqtJr" rel="nofollow" target="_blank" title="">https://assets.roche.com/f/176343/x/fca190f63e/fb25e.pdf</a></td></tr><tr><td style="text-align: left ; vertical-align: middle; vertical-align: top ; "> </td><td style="text-align: left ; vertical-align: middle; vertical-align: top ; "> </td></tr></table> Contacts Media contacts – <a href="https://www.globenewswire.com/Tracker?data=udMVPR6vhFvIWIWnXN9K-hp9-fq6lHF0ih6IRbiGZx5ahBd6g3vxHLBs1UYBPVYass2PeLU1-J_3jQ-RK8ncaQFn0WdJPzS4SS74ha1SUfOcg9ShJsu24mo6lWzuz8Ik" rel="nofollow" target="_blank" title="">alvotech.media@alvotech.com</a> Benedikt Stefansson Sarah MacLeod Investor Relations contacts – <a href="https://www.globenewswire.com/Tracker?data=udMVPR6vhFvIWIWnXN9K-iZr6UfqtzLvEN17aiGb3dWTAAdUHWg8ldExTxLE93J7j3npxRXY1Q0NwJsWE8ZOSLCqCS6_WroU_QYWO1ay-ufAUa0ytRioyhPxYV_gcuUX" rel="nofollow" target="_blank" title="">alvotech.ir@alvotech.com</a> Dr. Balaji V Prasad Benedikt Stefansson About Alvotech Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release. For more information, please visit our <a href="https://www.globenewswire.com/Tracker?data=xZUP5FWtdEhRc_aQgNZ8kAGiufjG5FJqv771WEFxhvu8Bpkle5vp06Dq3ohhPKcYQG9WfOS9mGMSrI6IXQM05Cx9xqmjwt3_xjhB-FLVzlogRjd756Po0vcI7-AFEs1_WP_CZFQkhnTEPFB24UgBOT_gFZMNhr0V6Y-r9-b-3FJYYAOGmUzynScWg7iJ5mxynrGp9CnjpT_4x5PipL9l1ky0P68BkUHxxnB7vgD0rVM=" rel="nofollow" target="_blank" title="website">website</a> or follow us on social media on <a href="https://www.globenewswire.com/Tracker?data=bmPVJzyLCKqm55FAzddBRJeB4rfLfUO9UQQttSvujLQ_vmnoDiBcKJ26PWPEl5l9xns6xa2gseQ4jWRXHIXZsZ-7v02-Ltk1e6SVwDW5W3z8LwkV1JHS4jJnsbf64FNuRukjjix4miWUgKXrs_NET4wKlgb63MWG4rppjzcC1qlXjj8IsrQT1nGslxcs-oEEQZwa83KYSrA1a10XGMM6X3LsttD5eepWSfmzEtOa2ZksQxDc1d1j3EbFhJ2MF-jv" rel="nofollow" target="_blank" title="LinkedIn">LinkedIn</a>, <a href="https://www.globenewswire.com/Tracker?data=ZAgLE8ATK_rL1PMqHJ2FFm6EcDZQJhqQEkKssvr-XCi0pjHmLjv7mBZyQs_5RMXY4bBcWgJwC0dnoMZWgWFNOtlB9YxusTH7f_j8yA0sq6E86UAiRc8LwXHTVRW3wk4dPpar9k6KFbVBk3MBFx8rDiy6hLJCo_3pXfLHdaF820V5_9KTtJ_d2cwYROj_r3cicThOhBldsW4XBAIwm2k-pQcyD1QaazuM2m5Ue51ZneUFnf9WyRvVxJ9TzdgbjJG2" rel="nofollow" target="_blank" title="Facebook">Facebook</a>, <a href="https://www.globenewswire.com/Tracker?data=YbwfnyYJIwy7ZbLYrL22O8CofGspd1fXuWekSzrPuiIVOIguy4xq-hUU2LcqWiADEkA3HQqvBCNGoQelduwndmYwW1oukXFRZacaAy5acIvJlsxsEnwDWmOvAO3Q-mS2soWSartGIE0fcN2GlEjUDLjyLT0ab6GAe-P9gKfJZGQz9UKH4D172SuFNgUPsFaH9zek102YUln097PdKsvIt0yDxDAzwF9IxTw6LxkhcIT30KkvqyVkFWO2ReUcKJs3" rel="nofollow" target="_blank" title="Instagram">Instagram</a>, and <a href="https://www.globenewswire.com/Tracker?data=QJYBR0Qpq21Uz7B39S_Rx-gWmp9cXXan4aY41o8-qfpZxJX3zvGXbCRgz4n0zldhcPQgi10sO0dDYlWsV4mscTX9tIRW5JZlkVA7t8CvpSEcxxiG0fPvK-k_H6KJySoka3ccG4HyrO1tQANm0csY0ViPIY_8l5L5hnVThOCWuk2-E7PDAWAjrxyGCi-VIMTO8ESZMGFkG8sl3utmlwk2DYl_-KgBhn2JuWhPClLyAUFEY7eQL1vZnxLHXLS7oHPd" rel="nofollow" target="_blank" title="YouTube">YouTube</a>. Forward Looking Statements Certain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, for example, Alvotech’s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, market launches and financial projections. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time-to-time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed. <img alt="" src='https://ml-eu.globenewswire.com/media/NjkxZmJkNjktMGEwMC00NjhjLTg5NjktYzZiOGZmMjRhYzhiLTEyNDUzODYtMjAyNi0wOC0yMS1lbg==/tiny/Alvotech.png' referrerpolicy='no-referrer-when-downgrade' />

LONDON, UK, Aug. 21, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- Artificial intelligence robots are moving beyond science fiction and becoming practical digital tools capable of analyzing information, making rule-based decisions, monitoring activity, and performing automated tasks. <img alt="" height="341" src="https://ml-eu.globenewswire.com/Resource/Download/18a32ef1-d9fe-4f30-be9c-690e65d8dd86/xrp.jpg" width="512" data-dpi="96" data-filename="XRP.jpg" /> In financial technology, these AI-powered systems are opening a new path toward automated market analysis and financial management. XRPPower is developing technology around this trend, combining artificial intelligence with quantitative analytics, automated trading systems, financial services, portfolio monitoring, and risk controls. From Traditional Automation to AI Robots <a href="https://www.globenewswire.com/Tracker?data=nlSR2GK1e1efskTMWAv6bv5cdFqOjVdNNYKqs_KanoeMehnb4EB0zsG31pncCIBPbn6gvQZ5rrh6cAqG14QUv8LDiBQpG33Rz3GWwkepTcq9hG6V0-NDmHNx3KvkgkCC1XvDGGlYSuEgZogTRP21UiTCtLcraVrG6otWDKOPUK7sKNQ7YLgDYJTiVuvFL9xWRE_bjdBMyhA8AfRxZZvH-rirCEJnSNP68QCKKEFJ3BF17wvIg4vHQi1WtuDqFwtGbRpH7ZRx8vqV0DeJg3xQ2ca_KG_iM6ZLpKBdeQd0kEec5qbxs-ptC7NayWJ3DqkICiJMHj5lf2ijc3lfr8YPSg==" rel="nofollow" target="_blank" title="">Traditional software follows fixed instructions. AI-powered robots can take automation further by processing large amounts of information and adapting their analysis based on available data</a>. In financial technology, an AI robot can continuously monitor market information, identify patterns, evaluate predefined conditions, and support automated strategies. XRPPower’s AI-powered systems are designed around these capabilities, using machine learning, market-data analysis, quantitative tools, and automated processes to support financial operations. The company’s recent technology developments include AI-powered trading systems designed to analyze market conditions and support automated strategy execution. Why AI Robots Matter to Investors The growing interest in AI robots is linked to a simple challenge: financial markets generate more information than individuals can easily process manually. AI-powered systems can work continuously, process multiple data points, and help organize information at high speed. For companies developing this technology, the opportunity extends beyond one trading function. AI robots can become part of a broader financial technology ecosystem supporting: - Market analysis - Quantitative research - Automated trading - Portfolio monitoring - Financial management - Risk monitoring - Account automation This broader use of AI could create new opportunities for financial technology companies as demand for intelligent automation grows. XRPPower’s AI Technology Focus <a href="https://www.globenewswire.com/Tracker?data=jeRsNxxxKRrdrdk73d_VK2LM_h8uyxakPYUdebvaZFNcAWRj8_-RfqAGGc-GtVwecXoAebRXgyyzMzGmuyzmcJW4AmsWo0WaEPxykIlclMg=" rel="nofollow" target="_blank" title="">XRPPower</a> is positioning artificial intelligence as an important part of its financial technology strategy. The company’s technology developments include AI-driven quantitative analytics, automated trading technology, market monitoring, portfolio tools, and security features. It has also introduced an AI-powered application designed to provide users with market insights and financial management tools. The company’s approach reflects a larger industry shift: AI is moving from a tool that simply provides information toward technology capable of supporting continuous analysis and automated action. The Road Ahead for AI Robots Artificial intelligence robots are still developing, but their potential applications are expanding rapidly. As AI becomes more capable, these systems could increasingly support financial research, market monitoring, portfolio management, customer services, and other digital operations. For XRPPower, the focus is on building technology that brings these capabilities together within a single financial technology ecosystem. The long-term opportunity will depend on factors including technology performance, security, transparency, responsible risk management, and user adoption. How to Register With XRPPower Users who want to explore the company’s AI-powered platform can register through the official website: Registration: <a href="https://www.globenewswire.com/Tracker?data=GVootDle3_m5JQeNzXgIfr2LJQ2TFJwhHRyMByxU_tpt3CwvoMuXBnx9_qW7jPyXJswF65qwPrOUsVGhjtaRZBtVOfp8cdThuvlPYyJ2qrWL4k5Qa2DCD1KiXesQjizm" rel="nofollow" target="_blank" title="">Register with XRPPower </a>Official website: <a href="https://www.globenewswire.com/Tracker?data=jeRsNxxxKRrdrdk73d_VK6ic7hPNJiwbkniVzAwscNgxrzSdiiNFSJz5yTw5GFjEtWKL3CmTBtboH5mGK_2Le5upzVZM2iVtKnCw_MMGERY=" rel="nofollow" target="_blank" title="">XRPPower</a> Users should review the platform’s available services, terms, and risks before using any financial service. About XRPPower XRPPower is a financial technology company focused on artificial intelligence, AI-powered automation, quantitative analytics, automated trading technology, financial management, security, and intelligent financial applications. The company develops technology designed to support data-driven financial services. Media Contact: Email: <a href="https://www.globenewswire.com/Tracker?data=d5IULvB9L0o9X_Q0cCraGjP7I3XvVpbD5bd9rP32yG5Sg1sHYYmn0asLnKqzRXBK5EzqO0S-TRXan1udZZqkgApF65qHQUEYh8Lx3rki7zEEhP4bRgUeUwiYFUTBakHaTZCbMH3uXmveiwjWovMljh5C9upRuAoR6HD8SivJPYDO6HuE5lPI1J25-Fg7tb8x-VYoY_J4naRxUfbK1Ux6JM7ZqbzutgF573mLJ1XyN3vGq-WyG6UvlJ15EO18MlHZvlTWQm_uBdbjGXQHvKsnNg==" rel="nofollow" target="_blank" title="info@xrppower.com/">info@xrppower.com/</a> <img alt="" src='https://ml-eu.globenewswire.com/media/MmZkYWMzMTYtZDYyOC00YTg4LWI3MWYtYjNmNTNiY2Y4MGQ0LTcwMDAyODAzNi0yMDI2LTA4LTIxLWVu/tiny/XRPPower.png' referrerpolicy='no-referrer-when-downgrade' />

XRPPower: Artificial Intelligence Robots Are Changing the Future of Digital Finance

MT Højgaard Holding’s business unit MT Højgaard Danmark has won the first phase of Copenhagen Airport's tender for the planning, design and construction of Baggage Factory East. The project is being tendered in a two-phase model. MT Højgaard Danmark has entered into a contract for the first phase and will develop and design the construction in collaboration with Copenhagen Airport, Artelia and ZESO Architects. The work in the first phase will be settled on a time and materials basis. After the collaboration phase, the intention is to enter into a turnkey contract for the second phase, where the project will be fully designed and constructed with a total estimated contract value of DKK 450 million from the third quarter of 2027 with expected delivery before the summer of 2030. As part of the construction, a long connecting bridge will be established for the transport of baggage between the new baggage factory and the existing Baggage Factory 3. MT Højgaard Danmark will thus build further on the experience from Baggage Factory West, which was delivered to Copenhagen Airport in 2021. The new baggage factory will support the airport's future capacity needs within baggage handling. "We look forward to continuing our close collaboration with Copenhagen Airport and our partners to develop and realise an important project that will support the airport's continued development and future capacity. We are proud to have been chosen for the assignment, which emphasises our strong position within complex projects with early contractor involvement," says Niels Holm Mikkelsen, CEO of MT Højgaard Danmark. The award does not affect MT Højgaard Holding’s 2026 outlook. Revenue is still expected at a level of DKK 10-10.5 billion with an operating profit (EBIT) of DKK 225-275 million. Further information: CEO Rasmus Untidt and CFO Dennis Nørgaard can be contacted on telephone +45 31 21 68 72. 
 Attachment

<ul id="gnw_attachments_section-items">
 <li>
 <a target="_blank" href="https://www.globenewswire.com/Tracker?data=kBeaTYTX1gB54nH8hwykbZEz-xV0EKZI7dqPvdVoFTocE-alUReLO5or0xQudbBtn7FfOs79BtCVyRRQd63_H50DZ4s2ZT7wnDoEy40kv4BmN6TNOw7EpEJf2_MHTSvDqqONiMvlxjmpa_WO-BFGHMWwoXc8rxnGDWjvVkwfhVQF16h2Q_bKvoHMu0LCxf09" title="MTHH_Investor news 21Aug26" rel="nofollow">MTHH_Investor news 21Aug26</a>
 </li>
 </ul>
 <img alt="" src='https://ml-eu.globenewswire.com/media/NjYzNjUxMmItYjU0My00NTBlLThkYzItOWMzZTNmMjJjZDlkLTExMDMxMjctMjAyNi0wOC0yMS1lbg==/tiny/MT-H-jgaard-Holding-A-S.png' referrerpolicy='no-referrer-when-downgrade' />

MT Højgaard Holding A/S: MT Højgaard Danmark wins tender from Copenhagen Airport

To Nasdaq Copenhagen and the Press 21.08.2026 Refinancing of floating rate loans The Nykredit Group has completed the auctions in connection with the refinancing of floating rate loans on 1 October 2026. The results of the auctions are shown below. The spreads will be in force until the next refinancing. <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="width:11.51%;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; "> </td><td style="width:13.57%;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">Euribor-loan</td><td style="width:12.46%;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">Euribor-loan</td><td style="width:12.46%;;border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">Euribor-loan</td></tr><tr><td style="width:11.51%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">ISIN</td><td style="width:13.57%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">DK000955434-7</td><td style="width:12.46%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">DK000955442-0</td><td style="width:12.46%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">DK000955450-3</td></tr><tr><td style="width:11.51%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">Reference rate</td><td style="width:13.57%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">Euribor3M</td><td style="width:12.46%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">Euribor3M</td><td style="width:12.46%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">Euribor3M</td></tr><tr><td style="width:11.51%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">Cover pool</td><td style="width:13.57%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">H (SDO)</td><td style="width:12.46%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">G (RO)</td><td style="width:12.46%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">G (RO)</td></tr><tr><td style="width:11.51%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">Series</td><td style="width:13.57%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">32H</td><td style="width:12.46%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">32G</td><td style="width:12.46%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">32G</td></tr><tr><td style="width:11.51%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">Callable</td><td style="width:13.57%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">No</td><td style="width:12.46%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">No</td><td style="width:12.46%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">Yes (100)</td></tr><tr><td style="width:11.51%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">Interest rate cap</td><td style="width:13.57%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">No</td><td style="width:12.46%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">No</td><td style="width:12.46%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">No</td></tr><tr><td style="width:11.51%;;border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">Auction results</td><td style="width:13.57%;;text-align: center ; vertical-align: middle; vertical-align: middle ; "> </td><td style="width:12.46%;;border-right: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; "> </td><td style="width:12.46%;;text-align: center ; vertical-align: middle; vertical-align: middle ; "> </td></tr><tr><td style="width:11.51%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">Total allotment</td><td style="width:13.57%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">EUR 1,175 mio.</td><td style="width:12.46%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">EUR 60 mio.</td><td style="width:12.46%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">EUR 70 mio.</td></tr><tr><td style="width:11.51%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">Total bids </td><td style="width:13.57%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">EUR 3,544 mio.</td><td style="width:12.46%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">EUR 106 mio.</td><td style="width:12.46%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">EUR 134 mio.</td></tr><tr><td style="width:11.51%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">Interest rate spread</td><td style="width:13.57%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">+0.26%</td><td style="width:12.46%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">+0.35%</td><td style="width:12.46%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">+0.41%</td></tr><tr><td style="width:11.51%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">Price</td><td style="width:13.57%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">100.20</td><td style="width:12.46%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">100.20</td><td style="width:12.46%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">100.20</td></tr><tr><td style="width:11.51%;;border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">Other information</td><td style="width:13.57%;;text-align: center ; vertical-align: middle; vertical-align: middle ; "> </td><td style="width:12.46%;;border-right: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; "> </td><td style="width:12.46%;;text-align: center ; vertical-align: middle; vertical-align: middle ; "> </td></tr><tr><td style="width:11.51%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">Maturity</td><td style="width:13.57%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">01/10/2029</td><td style="width:12.46%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">01/04/2029</td><td style="width:12.46%;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: middle ; ">01/10/2030</td></tr></table> Enquiries may be addressed to Group Treasury, Emil Schmidt Andreasen, tel. +45 4455 2272. 
 Attachment

<ul id="gnw_attachments_section-items">
 <li>
 <a target="_blank" href="https://www.globenewswire.com/Tracker?data=55aN-cmRHPddpgvG3QMWX3-XYkRp0El_hzpdzX1Y1HfTh7j0FlrHDXr35ckVT_MrZBhNkUQJph1X_ZIbL_iImla4IQdm7dI6cqulxdPi4ALD5dQwLcenrmrZLocvnsm_J_1HQWhRZHWCEd6YFnUjyNCor60Il5q_jqMaS_P1OyLqO-Otovqr57B7p7966pGhsgKxg_IEkv-3MlBiPuuHmQ==" title="Refinancing of floating rate loans EUR" rel="nofollow">Refinancing of floating rate loans EUR</a>
 </li>
 </ul>
 <img alt="" src='https://ml-eu.globenewswire.com/media/ODQ5M2YzYzMtZWEwMi00ODUxLWI4MWItZDc2NzYxNzgyY2M3LTExMDY5MDYtMjAyNi0wOC0yMS1lbg==/tiny/Nykredit-Realkredit-A-S.png' referrerpolicy='no-referrer-when-downgrade' />

Refinancing of floating rate loans - Nykredit Realkredit A/S

GlobeNewswire Press Releases

Banco Comercial Português, S.A. informs about Interim report on the transactions conducted under the Share Buy-Back Programme

ADEPTS launches UAE’s first online ICV score calculator

DeHealth Foundation by Anna Bondarenko and Denys Tsvaig Surpasses $3.2 Million in Medical Aid to Ukraine

Ecualama Celebrates 2,800 Customer Reviews From Buyers Worldwide

Umicore - Transparency notification by BNP Paribas Asset Management Holding and BNP Paribas Cardif

Crypto News: New Crypto Presale Moonberg Taps $300,000 As XRP Price Prediction Targets $10

Form 8.3 -DCC plc

Correction: Final terms for bond admitted to trading 26th August 2026

LHV Group's own share acquisition transactions

Spieren voor Spieren wins Dutch F1® Allwyn Global Community Award to transform lives through adaptive sport

Form 8.3 - Gooch & Housego plc - Octopus Investments

Form 8.3 - Advanced Medical Solutions Group plc - Octopus Investments

EPSO-G group announces financial results for the first six months of 2026

FRO – Invitation to Q2 2026 Results Conference Call and Webcast

Final terms for bond admitted to trading 26th August 2026

Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets

Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets

XRPPower: Artificial Intelligence Robots Are Changing the Future of Digital Finance

MT Højgaard Holding A/S: MT Højgaard Danmark wins tender from Copenhagen Airport

Refinancing of floating rate loans - Nykredit Realkredit A/S